An e-mail asks what did I think of Viola's Warrior King or whatever the crap title is?
I'm not seeing that. I was serious about how fatty is wrong for an action film. I don't want to look at her flabby gut and pretend she can do action. She can snarl and she can hiss. Seeing some flabby, hagged out actress pretend she's Douglas Fairbanks? Nope, not interested.
If she wants to do another WIDOWS, I'd probably see it. But she's not an action actor and she can't overcome her physical liabilities.
We watched NETFLIX tonight to see Sarah Michelle Gellar's movie. DO REVENGE is a really strong movie. It's an update on STRANGERS ON A TRAIN -- Alfred Hitchcock's classic has been updated many times including with THROW MOMMA FROM THE TRAIN. This one is set in high school. SMG has a small supporting role but it's an important one and she is excellent. The movie is also very good. And it's a strong film. Again,, it's on NETFLIX.
Oh, it didn't show up when we pulled NETFLIX up on the TV. So my girlfriend searched "Sarah Michelle Geller." And it didn't show in the results. So she searched "DO REVENGE" and it came up. Currently, if you pull up the cast information on NETFLIX, it doesn't even have SMG's name in it. I'm talking about the page where you give it a thumbs up or a thumbs down.
Now I want to note this from an interview with Sally Field at DEADLINE:
The first time with Norma was such a shock from the moment that an audience saw it, which was in Cannes. And the reaction to it and I won the Palme d’Or (for Best Actress there) and I could almost not feel anything for that whole awards season. And luckily those award seasons then in those days, I’m sure you know, weren’t anything like they are now. They were very much more subdued. But still I couldn’t quite feel it, and when I won the [Oscar] I was so numb. It was so hard to get there, so hard. I had been, and I felt I was a nationwide joke in The Flying Nun. But you know lots of people come up to me and say “I loved The Flying Nun. I loved The Flying Nun.” I say, “That’s good. I don’t really understand why you did, but that’s okay.” I was 19, 20 and 21 and it was just not where I wanted to be. So it just was a battle that I didn’t know that I would really win. So I said to myself. “If I ever get here [the Oscars] again, I am going to own it. I am going to do it. I am going to let it be mine.” So that is how that happened.
THE FLYING NUN was a great show -- see my "Really pissed off by Sally Field" -- and GIDGET sucked. She was Shirley Temple with little boobies cooing to Daddy.
THE FLYING NUN wasn't Shakespeare, I get it. But for me, as a little kid, watching it Monday through Friday (syndication, I wasn't alive when it was originally aired), it was pretty amazing. And I was excited by that show as I was by the 60s BATMAN show and more excited than I was by George Reeves' SUPERMAN. It was a great show and that's why it continues to air.
It's amazing that this is that hard for Sally Field to grasp in a century that has made so much out of Captain America, Iron Man, et al. Those are not great dramatic roles. But with a solid actor, they are characters that we respond to.
Going out with C.I.'s "Iraq snapshot:"
Friday, September 16, 2022. We note the fluff parade that still has ended over a recent death, Iraq remains mired in the stalemate and the US Senate talks monkeypox.
Senator Patty Murray: According to the Centers for Disease Control and Prevention, the U.S. now has over 21,000 confirmed cases of monkeypox -- more than anywhere else in the world, and my home state of Washington has over 500 cases. I've heard from families who are rightly concerned by how bad this has gotten. And public health officials -- including back in Washington state -- who are frustrated to see our response run into issues we should be prepared for by now. That’s why I continue to push the Biden Administration about my concerns with the monkeypox response, and urge quick action: on testing, treatments, and vaccines, and on clear guidance to the public, health care providers, and state public health officials. So it's reassuring to see we are making progress. On testing, capacity has increased one thousand percent, and FDA just approved a faster track for additional tests. On vaccines, BARDA is helping to stand up a new vaccine fill and finish site in Michigan, HHS is working to expand the number of distribution sites in states, and the Administration's advice for splitting doses has greatly stretched our vaccine supply. On outreach, the Administration has started working with states to make vaccines available at events with many people from the LGBTQ+ community in attendance. And perhaps most importantly -- the rate of new cases is going down. Now that is all encouraging news, but let me be clear -- we must remain vigilant in our response. And these promising improvements don;t excuse the issues I have been hearing about from communities, state health officials, and advocates from the start of this outbreak. Patients have spoken out about how hard it is to get tested -- some even waited days, despite having clear symptoms. Providers have had to jump through hoops to get their patients treatments. And I'm constantly talking to public health officials in my home state of Washington, who have told me how communications with states could have been far clearer -- and faster, and how the challenges in accessing tests and vaccines have delayed our response. I know states have especially struggled with the federal government's decision to forgo the system we typically use to distribute vaccines, the one we are already using for COVID vaccines. When it comes to vaccine distribution, some shipments have been sent to the wrong state, and even spoiled after storage at the wrong temperature. There have been issues with vaccine supply too -- like when thousands of vaccine doses were delayed because FDA had yet to inspect the new plant they were from, or when the Biden Administration missed an opportunity to procure more vaccines at a crucial point in this outbreak. And again, we are seeing inequities worsen this outbreak for some communities. Advocates in the LGBTQ+ community -- who have faced the vast majority of cases -- have also made clear they feel they are being overlooked, or in some instances stigmatized. We need to keep focusing and improving on outreach and on getting information and resources -- like vaccines-- to those who are most in need, and most at risk. And that must include communities of color, who we know don't have equitable access to vaccines. This is especially important as early data suggest Black and Latino communities are disproportionately burdened by this outbreak. We must do better. We need to be applying what we learned from the COVID response, and providing the resources communities have made clear they need. Of course, there is an enormous difference between this and the COVID pandemic, which is: thanks to decades of investment in smallpox research, we already had tests, treatments, and vaccines ready to go before this crisis even began. That should serve as a reminder to all of us about the immense value of investing in public health preparedness. But it's also why the stumbles in getting these tools deployed were especially frustrating and inexcusable. To learn from this, we need to be clear-eyed about what went wrong. Not just on challenges we faced in the last several months, but that we have faced for decades --challenges that, to be frank, have spanned many Administrations, not just this one. For example, we had over 20 million vials of smallpox vaccine in our national stockpile -- but they weren;t replaced as they expired over the course of a decade. I know I join my Ranking Member and members of this Committee when I say we have to do better -- not just on COVID, not just on monkeypox -- but on public health threats, period. Because we know there will be more. Just last week New York declared an emergency due to polio -- yet another public health risk we need to watch closely. So I want to hear from our witnesses today about not just what they are doing right now to improve our response to the monkeypox outbreak -- and fast -- but also how we can fix this in the long term and make sure the stumbles of the past couple months never happen again. I want to know what you and the Administration are doing to make sure we have enough tests, treatments, and vaccines for this outbreak-- and get them where they need to go while also maintaining an adequate stock of supplies for any smallpox threats. What are you doing to improve outreach to the LGBTQ+ community, address the disproportionate harm to Black and Latino communities, fight stigma and misinformation, and right the inequities we[ve seen in our response so far? How are we making the most of new research to develop promising vaccines and therapeutics, and then make them more quickly available -- while continuing to uphold the gold standard of safety and effectiveness? And are we getting schools and colleges everything they need to stay open and keep students and the school community safe? I'm glad CDC has provided guidance for K-12 schools -- and fortunately the science tells us elementary and secondary school kids are not at high risk right now, and CDC has also released resources for colleges which is critical with students returning to campus this fall. We need to make sure colleges and universities are equipped to prevent potential outbreaks as students move into dorms and live in close quarters with each other. I realize you've got your work cut out for you on all of this, especially with COVID still raging -- but there's no reason for us to fall behind. So I'm going to keep pushing you here, because families back in Washington state and across the country are counting on you to get it right. That's also why I'm going to keep pushing my colleagues here in Congress about the need for funding to support all this work. I know I'm not the only one here with concerns about the monkeypox response but we can't just say 'this isn't working' without providing the funding to end this outbreak and build the public health system Americans deserve. So I will continue to work with colleagues on both sides of the aisle, and push to deliver the resources that will help get families the testing, treatments, and vaccines they need. And I'm interested in hearing from the witnesses on what the needs are when it comes to investing in our monkeypox response. It is also important to me we continue to keep our eyes on the horizon when it comes to future outbreaks and pandemics, and build a stronger public health system for whatever threat comes next. As the saying goes -- an ounce of prevention is worth a pound of cure. That starts with building a world class public health system, rather than one that lags behind our peers. Our communities deserve to be as safe as anyone in the world, which is why Senator Burr and I are continuing to work to pass our PREVENT Pandemics Act. Our bipartisan legislation implements the lessons from our COVID response and improves our policies and processes on issues like strengthening supply chains, improving management of our national stockpile, modernizing data systems, and other items which would address many of the challenges we've faced with monkeypox. But a strong public health system also requires strong investments. Because our public health system was underfunded before COVID struck -- and it has been overwhelmed ever since. We have to end the cycle of crisis and complacency by making sustained investments that allow us to build, and maintain, robust public health infrastructure at all levels. And I'm going to keep pushing for all of these steps, because we should all know by now just how much is at stake. I can tell you, families in Seattle know, parents in Spokane know, nurses in Yakima know, workers in Olympia know, people across Washington state, and across the country, know: COVID was never going to be the last public health crisis we face -- and neither is monkeypox. The question is not whether there will be a new threat -- it is when it will strike and whether we will be ready. The truth is, the monkeypox response so far has not been encouraging -- but there are some clear signs of progress, and there are clear steps we can, and should, take to improve. And I don't just want to hear today about the steps you will be taking -- I want to see action. And you better believe I'll be watching closely.
She was speaking Wednesday at the US Senate Committee on Health, Education, Labor and Pensions. Appearing before the committee were Dr Rochelle Walensky (Director of the CDC), Dawn O'Connell (Assistant Secretary for Preparedness and Response), Dr. Robert Califf (FDA Commissioner) and Dr Anthony Fauci (NIH Director). Murray is the Committee Chair, Senator Richard Burr is the Ranking Member.
Committee Chair Patty Murray: [. . .] I say, frankly, too many missteps were made early on in the response and a couple hundred cases turned into 21,000. It is unacceptable to communities who already experience barriers to accessing healthcare like the LGBTQ+ and the Black and the Latino communities that are hardest hit by this outbreak. Access to testing was an early challenge in the monkeypox response with many people reporting significant delays in both accessing the test and learning their results. To continue to have these challenges around testing is just simply unacceptable. So, Dr Walensky, let me start with you. How is the CDC working to make sure that tests are more accessible and results are available earlier?
Dr Rochelle Walensky: Thank you, Senator, for that question. One of the big challenges that we had in terms of access to testing was both patients understanding that they were presenting with a new infection and providers understanding that this was a new infection that they had to test for. Indeed, another important clinical consideration was that people were coming in requesting a test when they had no symptoms and they had no rash. As Dr Califf noted, the test for this infection is a swab of the rash so if there is no other FDA approved test, we need to have a rash in order to conduct those tests. So much of what we've done -- and I should mention that we've always had more capacity than we've had tests coming in -- to date, we've used about 14 to 20% of our capacity. But to address these access issues, we had to work with clinicians, we had to work with patients, we had to do an extraordinary amount of outreach so that providers would understand how to test, patients would understand when to come in for a test and our public health partners would know not to gatekeep those tests. And so that was a work that we did early on.
Yes, Walensky, and that is your job. That is your defined job. That's what the CDC does. Stop making excuses and pretending you were suddenly tasked with new responsibilities.
Chair Patty Murray: Dr Califf, Secretary [Xavier] Becerra recently declared that FDA can use the emergency use authorization pathway for monkeypox tests. How will that improve the availability of new tests and what steps are you taking to improve on the progress that you've made?
Dr Robert Califf: First of all, let me concur with Dr Walensky, there's never been a shortage of tests but there's been a shortage of access to tests because of inefficiencies in the system so the EUA authority has enabled us -- we've given one EUA already but we also have five commercial labs which are offering the tests at this point and we issued a guidance just the other day which, uhm, makes it clear that individual institutions that are developing laboratory developed tests should proceed ahead and we've given people clear guidance templates for developing their tests and figuring out if they work. So I'd say, on all fronts, the gates are open under a watchful eye because we also must keep in mind that one of the lessons from COVID was that when the gates were open a lot of the tests turned out to be not so good, got a lot of them out there and we had to reign them back in.
Chair Patty Murray: I -- Well, look. I'm encouraged by the declining cases. But it really is imperative that we remain vigilant. And despite efforts by HHS to increase access to vaccines, some people in my home state of Washington still go to great lengths to get one -- including crossing the border into Canada to get one. Now people, understandably, want to be vaccinated before they get exposed but that means we need more vaccines. Ms. O'Connell, some serious stumbles were made this year when it came to our vaccine supply. What have you done to make sure that never happens again? And what are you doing to increase the supply and distribution of vaccines right now.
Dawn O'Connell: Chairman Murray, thank you so much for that question. What's most important to us is that those who need access to this vaccine get it. So if you continue to hear from constituents that are unable to access the vaccine or having to cross the border, please let us know. We are in the business right now of knocking down those hurdles and making sure the vaccine can be accessed. We did take a very small stockpile that was intended for small pox that was eventually intended to be lyophilized -- freeze dried -- for small pox and converted it to this active monkeypox response. And that required a couple of challenging problems to solve. We moved the fist 372,000 vials, as I mentioned in my opening statement, immediately. We needed FDA to approve -- and they were terrific partners moving quickly -- to approve that second manufacturing line that began, uh, drew the 800,000 vials we were waiting for. That's what it manufactured on. We needed that approval to happen before we could deploy those. FDA worked quickly and we got those out in July. We have also ordered an additional 5.5 million vials of the bulk drug substance that was intended to be lyophilized for small pox -- we have ordered that to be filled and finished and shipped to the United States. And the 2.5 million of those will be manufactured in the United States.
The hearing can best be summed up with one statement from Ranking Member Richard Burr, "You failed on vaccines."
There's no real progress here and things haven't changed much since Senator Murray sent the following letter last month:
The Honorable Xavier Becerra
Department of Health and Human Services
200 Independence Ave SW
Washington, DC 20201
Dear Secretary Becerra:
The United States is reporting a historically high number of monkeypox cases with over 1,970 cases confirmed in 43 states, the District of Columbia, and Puerto Rico. As I have raised on multiple calls with the Administration, I am concerned with the state of the U.S. response to monkeypox. The spread of monkeypox is a reminder that our work to protect families and strengthen our preparedness and response system is far from complete and cannot end with the COVID-19 pandemic. Communities across the country are relying on you to do everything you can to protect them from the threat of monkeypox. I write to request a briefing from the Department of Health and Human Services (HHS or the Department) on the domestic response to the monkeypox outbreak, including understanding how it is applying the lessons learned from the COVID-19 response, as well as the additional resources and authorities it needs to respond to and stop the disease from spreading further.
The global monkeypox outbreak was first reported to the World Health Organization (WHO) in May 2022, and today, 13,340 cases related to this outbreak have been detected in 69 countries. Over the last two years, the COVID-19 pandemic has not only highlighted the dangers of a fragmented, understaffed, and underfunded public health system, but has put an unprecedented strain on our front line public health and health care workers, who are now being tasked with addressing yet another emerging public health threat. It is critical that lessons from COVID-19 are incorporated into our monkeypox response.
HHS has already taken a number of steps to respond to the domestic monkeypox outbreak, include activating the Centers for Disease Control and Prevention’s Emergency Operations Center, releasing updated guidance and training for health care providers, mobilizing the Laboratory Response Network and working with commercial labs to expand testing capacity, deploying medical countermeasures, and releasing a vaccination strategy for close contacts.,
However, it is clear more work is necessary to ensure that public health officials at all levels have the information and resources they need to respond quickly to this outbreak.
Various reports indicate challenges at the local level, with some patients and providers stating they do not have the information and resources necessary to understand, test for, or respond to the disease, which is now presenting with uncharacteristic features.,,, Since the disease spreads through close, intimate contact, some patients are seeking care at sexual health clinics, which are frequently under-resourced despite providing critical services to underserved communities, including the LGBTQ+ community.
Ensuring the public health system responds appropriately to monkeypox will require both decisive action from the Department and its state, local, and Tribal partners, as well as robust, sustained investments in public health. History repeatedly shows the critical importance of providing long-term investments in our public health and medical response systems to ensure the U.S. is prepared to respond to a variety of threats. The global eradication of smallpox, a virus in the same family as monkeypox, is a public health success story – and is a credit to sustained, bipartisan investment into the research and development of medical countermeasures. The federal government stockpiled countermeasures, practiced responses with state and local health departments, and educated the public about smallpox.
While this investment in countermeasures has been sustained over decades, funding for the broader U.S. public health system has instead been subject to a cycle of crisis and complacency. That lack of consistency is why I have pushed for passage of the Public Health Infrastructure Saves Lives Act, which would provide the sustained funding we need to handle emergencies such as monkeypox or COVID-19. Additionally, to ensure HHS has additional tools to respond efficiently to public health emergencies, I have worked with Senator Burr on our bipartisan PREVENT Pandemics Act.
Given the continued spread of this virus and the need to ensure that all public health officials have the guidance and resources necessary to respond, I request a briefing by August 2, 2022 to better understand both HHS’s immediate response and the additional resources and authorities it needs. Specifically, I request updates on: (1) HHS’s plan for responding to the current domestic monkeypox outbreak, including the guidance being provided to state, local, and Tribal health departments and to health care providers; (2) the current status of monkeypox vaccines, tests, and therapeutics, including their manufacture and guidance on the distribution of those countermeasures; (3) an overview of how the Department is applying lessons from the COVID-19 response to the monkeypox response; and (4) what additional resources or authorities are needed to respond to and stop the disease from spreading further.
Thank you in advance for your attention to this matter. Please direct correspondence pertaining to this request to Jane Bigham at Jane_Bigham@help.senate.gov or Greg_Carter@help.senate.gov.
Maybe the next hearing can find witnesses less eager to pat themselves on the back and more willing to offer apologies to the citizens of this country for the lousy response.
THE WASHINGTON POST's Dan Diamond Tweeted this regarding the hearing.
Turning to Iraq, at FOREIGN POLICY, Ahmed Twaij offers an analysis of the ongoing stalemate:
The catastrophic spiral of events that peaked with parts of Baghdad turning into a war zone was triggered by a largely overlooked statement by a religious leader. On Aug. 28, the Iraqi Shiite spiritual leader Ayatollah Kadhim al-Haeri shockingly announced his retirement from his position of religious authority with immediate effect. More surprisingly, Haeri proceeded to ask his followers to back Iran’s Ayatollah Ali Khamenei instead. Although Haeri is unknown to most outside Iraq and even to some Iraqis, he is a highly influential spiritual leader (marji) for Sadr’s supporters.
One central doctrine in Shiite Islam is the concept of marjiya, which is the need for every Shiite Muslim to have a selected spiritual leader whose edicts and fatwas are unquestionably followed. In order to become a marji, a religious cleric must go through decades of religious studying, as well as earn the support of fellow senior clerics, before being given the title of ayatollah. In Iraq, it is Ayatollah Ali al-Sistani who yields the greatest influence over spiritual decrees, and he chooses to maintain a distance from politics. In Iran, however, the marji is the country’s supreme leader, Khamenei, who is very much involved in ruling his own country and attempting to influence its neighbor Iraq.
Moqtada’s father, Ayatollah Mohammed al-Sadr, did have the qualifications to be both a spiritual leader and political leader. But upon the elder Sadr’s assassination in 1999, his loyalists split their political and religious allegiances. As the younger Sadr is not a qualified marji, his supporters—duty bound, according to Shiite Islam, to follow another cleric on matters of belief—turned to Haeri, who had earned the elder Sadr’s endorsement, for religious guidance.
Haeri’s decision to resign from religious authority is unprecedented in the marjiya system. The role is one usually held until death, regardless of age or well-being. Sistani, for example is 92 and continues his duties. Ayatollah Mohammed Hussein Fadlallah continued on as a marji despite his multiple hospitalizations, right up until his death in 2010. It is also not common for a living ayatollah to appoint his successor, much less for an Iraqi ayatollah to recognize the religious authority of Iran’s clerical city of Qom over the Iraqi city of Najaf. For Haeri to ambiguously claim health-related issues at the age of 83—the same age as Khamenei—and to endorse Khamenei as his successor suggests Iran’s political influence was at work in his decision, with an aim toward reducing Sadr’s influence.
Let's note this Tweet from John Pilger:
And that brings us to the topic of the fluffing that never ends over the 'shocking' death of a 96-year-old -- so young!!! Taken so soon! Robert Stevens (WSWS) notes:
Amid the mind-numbing eulogies to Queen Elizabeth II, it is frequently asserted that she was “one of us” and “everyone’s grandmother”.
Commentator Andrew Marr, a pillar of the media establishment, wrote a fawning comment the Times, headlined, “Queen Elizabeth II: the majestic enigma who was one of us”. He went as far to declare, “During the rawest, roughest years of the Thatcherite experiment, the Queen even seemed dryly oppositionist.”
This claim has been made throughout the media and parroted in ruling circle everywhere. Nothing was ever further from the truth. The queen heads a family of billionaires and lived a life of fabulous and unearned wealth and privilege. She ended her reign at Balmoral Castle, her £140 million private residence, as over 14 million of her “subjects”, including over 4 million children, live in poverty.
As well as Balmoral, Sandringham, valued at £600 million, was also privately owned by the queen.
Everything she and her family and relatives possesses is thanks to centuries of pillage and plunder by her forebears. Moreover, most of this staggering wealth is assiduously protected from taxation by the state.
The fortune of the monarch is shrouded in secrecy, but it runs into the many billions of pounds.
According to the Sunday Times Rich List, the queen was personally worth around £370 million. But this was only identifiable wealth. The Paradise Papers, leaked in 2017, show that among the queen hidden dealings, via the Dutchy of Lancaster estate she owned, was the parking of millions of pounds in a Cayman Islands fund. Part of that fund went to a retailer, BrightHouse, cited for exploiting poor UK families through its hire-to-own scheme.
Isaiah's THE WORLD TODAY JUST NUTS "The Question" went up and the following sites updated:
Post a Comment